Page updated ·next FDA decision on the calendar·Data as of Nov 5, 2026 5:03 AM ET
FDA decision (PDUFA) target May 13, 2027 · Bristol-Myers Squibb Company · Relapsed or refractory multiple myeloma
Source: Bristol Myers Squibb 8-K 2026-07-30 (EX-99.1, Q2 2026 results). “…for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma (RRMM), granting a PDUFA date of May 13, 2027”
The FDA PDUFA target date for BMY (Bristol-Myers Squibb Company) is 2027-05-13 for Mezigdomide. Dates are company/FDA-sourced and can slip. Verify against primary filings.
What is BMY's drug Mezigdomide?
Mezigdomide is Bristol-Myers Squibb Company's candidate under FDA review for Relapsed or refractory multiple myeloma.